Effects of pitavastatin on walking capacity and CD34+/133+ cell number in patients with peripheral artery disease

Arao, Kenshiro; Yasu, Takanori; Endo, Yasuhiro; Funazaki, Toshikazu; Ota, Yoshimi; Shimada, Kazunori; Tokutake, Eiichi; Naito, Naoki; Takase, Bonpei; Wake, Minoru; Ikeda, Nahoko; Horie, Yasuto; Sugimura, Hiroyuki; Momomura, Shin‐ichi; Kawakami, Masanobu

doi:10.1007/s00380-017-0988-1

Cited by 9 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PAD is mostly due to atherosclerosis, which leads to progressive obstructions of peripheral arteries. When pharmacological therapy (lipid-lowering ( 3 ) and antihypertensive drugs ( 4 ) and life-style changes [diet, exercise…( 5 )] fail and PAD progresses to critical limb threatening ischemia (CLTI), vascular surgery remains the only option ( 1 , 2 ). However, surgery may fail to relieve symptoms, or may not be possible due to the anatomy, severity of the disease or comorbidities.…”

Section: Introductionmentioning

confidence: 99%

Sodium thiosulfate, a source of hydrogen sulfide, stimulates endothelial cell proliferation and neovascularization

Macabrey

Joniová

Gasser

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Therapies to accelerate vascular repair are currently lacking. Pre-clinical studies suggest that hydrogen sulfide (H2S), an endogenous gasotransmitter, promotes angiogenesis. Here, we hypothesized that sodium thiosulfate (STS), a clinically relevant source of H2S, would stimulate angiogenesis and vascular repair. STS stimulated neovascularization in WT and LDLR receptor knockout mice following hindlimb ischemia as evidenced by increased leg perfusion assessed by laser Doppler imaging, and capillary density in the gastrocnemius muscle. STS also promoted VEGF-dependent angiogenesis in matrigel plugs in vivo and in the chorioallantoic membrane of chick embryos. In vitro, STS and NaHS stimulated human umbilical vein endothelial cell (HUVEC) migration and proliferation. Seahorse experiments further revealed that STS inhibited mitochondrial respiration and promoted glycolysis in HUVEC. The effect of STS on migration and proliferation was glycolysis-dependent. STS probably acts through metabolic reprogramming of endothelial cells toward a more proliferative glycolytic state. These findings may hold broad clinical implications for patients suffering from vascular occlusive diseases.

show abstract

Section: Introductionmentioning

confidence: 99%

Sodium thiosulfate, a source of hydrogen sulfide, stimulates endothelial cell proliferation and neovascularization

Macabrey

Joniová

Gasser

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Additionally, it was found that statin treatment was associated with superior leg function compared with no statin use, independently of cholesterol levels [9]. Claudication symptoms and walking performance were improved among patients treated with statins [10, 11]. Combination of atorvastatin with cilostazol had a synergistic effect on infarct size-limitation and on myocardial levels in rats through activation of endothelial nitric oxide synthase [12].…”

Section: Introductionmentioning

confidence: 99%

Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects

Kim

Jung

Kim

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Purpose We evaluated potential drug-drug interactions between cilostazol and simvastatin, both CYP3A substrates, in healthy subjects. Methods An open-label, two-period, fixed-sequence clinical study was conducted. Seventeen subjects were given a single oral dose of simvastatin 40 mg on day 1 and multiple oral doses of cilostazol 100 mg twice daily on days 2 to 5 followed by a single dose of cilostazol and simvastatin on day 6. Plasma concentrations of simvastatin and its active metabolite, simvastatin acid, were measured using liquid chromatography-tandem mass spectrometry for pharmacokinetic assessment. Moreover, serum lipid profiles under fasting conditions were determined. Results The geometric mean ratios of the area under the plasma concentration-time curve from time zero to time infinity of simvastatin combined with cilostazol to that of simvastatin alone were 1.64 (90% CI, 1.38-1.95) for simvastatin and 1.31 (1.04-1.66) for simvastatin acid. In addition, coadministration with cilostazol significantly increased the maximum concentration of simvastatin and simvastatin acid, up to 1.8-fold and 1.6-fold, respectively. However, the effects of a single dose of simvastatin on serum lipid profiles were not affected notably when simvastatin was coadministered with cilostazol. Conclusions Multiple doses of cilostazol increased the systemic exposure of simvastatin and simvastatin acid following a single dose of simvastatin.

show abstract

“…7 Arao et al evaluated the effect of short-term pitavastatin on asymptomatic walking distance and maximum walking distance in patients with PAD. 46 Of the 75 patients, use of pitavastatin in 53 patients was associated with improved asymptomatic walking distance and maximum walking distance.…”

Section: Statinsmentioning

confidence: 92%

Lipid-lowering therapies in peripheral artery disease: A review

et al. 2020

View full text Add to dashboard Cite

Peripheral artery disease (PAD) is estimated to affect approximately 8.5 million individuals in the US above the age of 40, and is associated with significant morbidity, mortality, and impairment. Despite the significant adverse limb and cardiovascular (CV) outcomes seen in patients with PAD, there is typically less attention paid to risk factor modification relative to other atherosclerotic diseases such as coronary artery disease (CAD) or stroke. In the current literature, statins have been shown to reduce mortality, major adverse CV events, major adverse limb events, and improve symptomatic outcomes in patients with PAD. In addition, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are emerging as an additional lipid-lowering therapy for patients with PAD. However, despite current guideline recommendations based on growing evidence, PAD patients are consistently undertreated with lipid-lowering therapies. We provide an extensive literature review and evidence-based recommendations for the use of statins and PCSK9 inhibitors in patients with PAD.

show abstract

Effects of pitavastatin on walking capacity and CD34+/133+ cell number in patients with peripheral artery disease

Cited by 9 publications

References 39 publications

Sodium thiosulfate, a source of hydrogen sulfide, stimulates endothelial cell proliferation and neovascularization

Sodium thiosulfate, a source of hydrogen sulfide, stimulates endothelial cell proliferation and neovascularization

Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects

Lipid-lowering therapies in peripheral artery disease: A review

Contact Info

Product

Resources

About